Lung Cancer
Combination of Introgen's nanoparticles demonstrates increased efficacy in metastatic lung cancer
Published in Cancer Weekly, February 13th, 2007
Molecular cancer therapies using these genes, p53 and FUS1, are in clinical-stage development by Introgen Therapeutics (INGN). The technologies are included in a broad portfolio of intellectual properties licensed exclusively to Introgen from M. D. Anderson Cancer Center and other institutions.
The study, published in the January 15 issue of the journal Cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-02-13)
More Articles from Cancer Weekly
- Cancer Gene Therapy
Data from Johns Hopkins Medical Institutions, Department of Pathology advance knowledge in cancer gene therapy - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Hokkaido University - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at University of Maryland, Department of Radiation Oncology - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at University of Brescia - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at University of Helsinki, Haartman Institute - Cancer Gene Therapy
Investigators at Queen Mary Hospital zero in on cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
